GlassScriptPhysician profile
Julia D Nicholson
NPI 1740415611
$3,238.23
in general payments reported to CMS, 2019-2025
31 companies · $17.33 in 2025
The $17.33 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $425 · 2021: $825 · 2022: $98.05 · 2023: $549 · 2024: $414 · 2025: $17.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $530.18 | 2020-2024 | |
| Glaxosmithkline, LLC. | $374.16 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $320.80 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $276.59 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $248.59 | 2019-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $199.76 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $154.61 | 2019-2024 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $128.33 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $123.60 | 2019-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.48 | 2020-2023 | Xifaxan, Trulance |
| Astellas Pharma US INC | $90.80 | 2019-2021 | |
| Allergan, INC. | $90.64 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $70.65 | 2020-2021 | |
| Shield Therapeutics INC | $67.10 | 2023 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $52.64 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $48.56 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $46.59 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $40.75 | 2020-2021 | |
| Esperion Therapeutics, INC. | $36.19 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $33.52 | 2023-2024 | Rexulti |
| Genentech USA, INC. | $27.49 | 2020 | |
| Sunovion Pharmaceuticals INC. | $26.12 | 2019 | |
| Lilly USA, LLC | $22.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.24 | 2024 | Jardiance |
| Dexcom, INC. | $19.21 | 2024 | Dexcom G6 Transmitter |
| Sun Pharmaceutical Industries INC. | $18.65 | 2021 | |
| Irhythm Technologies, INC. | $17.01 | 2024 | Zio Xt Patch |
| Abbott Laboratories | $15.25 | 2021 | |
| Mylan Specialty L.P. | $14.57 | 2023 | Yupelri |
| Shire North American Group INC | $14.56 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.